On the stock market since 2010, it operates in the world of health and science. It has 17 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $10.8M in the vault; even if every debt were paid off, $10.8M would remain.
Over the last 12 months, company executives reported 29 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $7.2M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, EDSA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: EDSA is a high-risk stock — not yet profitable, and its future rides on its product catching on.